MDX-260

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMDX-260

Drug Alias NameMDX-260

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsNervous System NeoplasmsMelanomaGlioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMedarex Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedarex Inc

Active IndicationsN/A

Inactive IndicationsNervous System NeoplasmsMelanomaGlioma

Other Information

ATC CodeN/A